TY - JOUR
T1 - Anti-HIV activity and resistance profile of the CXC chemokine receptor 4 antagonist POL3026
AU - Moncunill, Gemma
AU - Armand-Ugón, Mercedes
AU - Clotet-Codina, Imma
AU - Pauls, Eduardo
AU - Ballana, Ester
AU - Llano, Anuska
AU - Romagnoli, Barbara
AU - Vrijbloed, Jan W.
AU - Gombert, Frank O.
AU - Clotet, Bonaventura
AU - De Marco, Steve
AU - Esté, José A.
PY - 2008/4/1
Y1 - 2008/4/1
N2 - We have studied the mechanism of action of Arg*-Arg-Nal2-Cys(1x)-Tyr- Gln-Lys-(D-Pro)-Pro-Tyr-Arg-Cit-Cys(1x)-Arg-Gly-(D-Pro)* (POL3026), a novel specific β-hairpin mimetic CXC chemokine receptor (CXCR)4 antagonist. POL3026 specifically blocked the binding of anti-CXCR4 monoclonal antibody 12G5 and the intracellular Ca2+ signal induced by CXC chemokine ligand 12. POL3026 consistently blocked the replication of human immunodeficiency virus (HIV), including a wide panel of X4 and dualtropic strains and subtypes in several culture models, with 50% effective concentrations (EC50) at the subnanomolar range, making POL3026 the most potent CXCR4 antagonist described to date. However, 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl) phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane (AMD3100)-resistant and stromal cell-derived factor-1α-resistant HIV-1 strains were cross-resistant to POL3026. Time of addition experiments and a multiparametric evaluation of HIV envelope function in the presence of test compounds confirmed the activity of POL3026 at an early step of virus replication: interaction with the coreceptor. Generation of HIV-1 resistance to POL3026 led to the selection of viruses 12- and 25-fold less sensitive and with mutations in gp120, including the V3 loop region. However, POL3026 prevented the emergence of CXCR4-using variants from an R5 HIV-1 strain that may occur in the presence of anti-HIV agents targeting CC chemokine receptor 5. Copyright © 2008 The American Society for Pharmacology and Experimental Therapeutics.
AB - We have studied the mechanism of action of Arg*-Arg-Nal2-Cys(1x)-Tyr- Gln-Lys-(D-Pro)-Pro-Tyr-Arg-Cit-Cys(1x)-Arg-Gly-(D-Pro)* (POL3026), a novel specific β-hairpin mimetic CXC chemokine receptor (CXCR)4 antagonist. POL3026 specifically blocked the binding of anti-CXCR4 monoclonal antibody 12G5 and the intracellular Ca2+ signal induced by CXC chemokine ligand 12. POL3026 consistently blocked the replication of human immunodeficiency virus (HIV), including a wide panel of X4 and dualtropic strains and subtypes in several culture models, with 50% effective concentrations (EC50) at the subnanomolar range, making POL3026 the most potent CXCR4 antagonist described to date. However, 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl) phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane (AMD3100)-resistant and stromal cell-derived factor-1α-resistant HIV-1 strains were cross-resistant to POL3026. Time of addition experiments and a multiparametric evaluation of HIV envelope function in the presence of test compounds confirmed the activity of POL3026 at an early step of virus replication: interaction with the coreceptor. Generation of HIV-1 resistance to POL3026 led to the selection of viruses 12- and 25-fold less sensitive and with mutations in gp120, including the V3 loop region. However, POL3026 prevented the emergence of CXCR4-using variants from an R5 HIV-1 strain that may occur in the presence of anti-HIV agents targeting CC chemokine receptor 5. Copyright © 2008 The American Society for Pharmacology and Experimental Therapeutics.
U2 - 10.1124/mol.107.042911
DO - 10.1124/mol.107.042911
M3 - Article
SN - 0026-895X
VL - 73
SP - 1264
EP - 1273
JO - Molecular Pharmacology
JF - Molecular Pharmacology
IS - 4
ER -
